Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
Validation of a biological score to predict response in chronic lymphocytic leukemia patients treated front-line with bendamustine and rituximab
复制标题
DOI：
10.1038/s41375-018-0100-6
复制
发表时间：
2018-08-01
期刊：
影响因子：
11.4
通讯作者：
Morabito, Fortunato
中科院分区：
文献类型：
--
作者：
Gentile, Massimo;Shanafelt, Tait D.;Morabito, Fortunato
在过去的二十年中，已经确定了慢性淋巴细胞白血病（CLL）[1]的几种生物学预后标志物。一些，如IGHV突变状态和TP53破坏，也可以预测对化学免疫治疗的反应[2-6]。Rossi等人报道了对404例一线治疗的CLL患者的观察性回顾性分析
During the the last two decades several biological prognostic markers have been identified in chronic lymphocytic leukemia (CLL)[1]. Some, like the IGHV mutational status and TP53 disruption, are also predictive of response to chemoimmunotherapy [2–6]. Rossi et al. reported an observational retrospective analysis on 404 CLL patients treated front-line